Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 10, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	3,232	5,098	2,224	1,563	1,606	818
Market Cap Growth	30.26%	129.18%	42.30%	-2.70%	96.45%	196.48%
Enterprise Value	3,445	5,038	2,144	1,482	1,572	801
Last Close Price	9.69	15.40	-	-	-	-
PE Ratio	227.25	165.02	626.21	-	-	-
PS Ratio	4.87	10.52	6.49	14.37	290.85	203.33
PB Ratio	7.66	14.50	21.91	28.75	1023.78	13.41
P/TBV Ratio	-	54.17	83.14	109.40	-	53.46
P/FCF Ratio	335.37	286.95	229.72	-	-	619.12
P/OCF Ratio	142.83	191.44	136.63	-	-	540.78
EV/Sales Ratio	5.19	10.39	6.26	13.62	284.54	199.24
EV/EBITDA Ratio	94.63	92.95	55.00	-	-	-
EV/EBIT Ratio	122.61	99.41	60.60	-	-	-
EV/FCF Ratio	357.50	283.58	221.37	-	-	606.68
Debt / Equity Ratio	0.99	1.02	0.12	0.13	1.18	0.03
Debt / EBITDA Ratio	10.42	6.47	0.30	-	-	-
Debt / FCF Ratio	43.40	20.26	1.23	-	-	1.29
Asset Turnover	0.79	0.82	1.52	0.88	0.06	0.04
Inventory Turnover	10.97	10.79	15.36	10.92	1.25	3.45
Quick Ratio	1.11	2.60	1.18	1.90	1.13	4.62
Current Ratio	1.33	2.78	1.41	2.03	1.25	4.69
Return on Equity (ROE)	3.14%	13.92%	4.55%	-253.34%	-198.36%	-60.21%
Return on Assets (ROA)	2.08%	5.33%	9.81%	-25.37%	-37.95%	-23.64%
Return on Capital (ROIC)	3.12%	7.78%	25.26%	-97.35%	-118.20%	-40.13%
Return on Capital Employed (ROCE)	3.20%	6.90%	21.50%	-	-	-
Earnings Yield	0.34%	0.61%	0.16%	-4.53%	-3.64%	-4.23%
FCF Yield	0.30%	0.35%	0.43%	-3.09%	-2.75%	0.16%
Buyback Yield / Dilution	37.99%	-6.64%	-4.21%	-10.08%	-9.69%	-10.21%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q